Alpha Tau Medical (DRTS) Cash from Operations (2021 - 2022)

Alpha Tau Medical (DRTS) posted quarterly Cash from Operations of 8743000.0 for Q2 2022, down 32.77% on a QoQ basis from 6585000.0 in Q1 2022.

Alpha Tau Medical (DRTS) Cash from Operations (2021 - 2022) Analysis & Trends

Alpha Tau Medical (DRTS) has reported Cash from Operations for 2 consecutive years, with 8743000.0 the latest figure, recorded in Q2 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Cash from Operations (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-19.59 Mn
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	201.34 Mn
4	NuCana	279.75 Bn	279.75 Bn	-	-1.53 Mn
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	1.43 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	1.08 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-354.17 Mn
10	Alpha Tau Medical	1.19 Bn	1.11 Bn	-	-

Download Data